Skip to evidence report

T.CD4_Treg.APC_interactive: Studies

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 3,777 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 1–1,000 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for T.CD4_Treg.APC_interactive
#Trait / studyIndividual trait IDMean IC score
1Other/unspecified rheumatoid arthritisFING0000112680.79
2Allergic contact dermatitisFING0000006861.85
3IL2RB levelsGCST9046958661.26
4Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers)FING0000075659.34
5Seropositive rheumatoid arthritis, strict definitionFING0000129754.90
6HyperthyroidismGCST9031931949.33
7Hypothyroidism (PheCode 244)GCST9047564747.84
8Hypothyroidism NOS (PheCode 244.4)GCST9047565346.57
9Myasthenia gravisGCST9043215646.36
10Nasal polyps (PheCode 471)GCST9047601945.92
11CD5 levelsGCST9046864145.69
12Reimbursement for rheumatic diseasesFING0000124745.02
13Preterm labour and deliveryFING0000120943.47
14Thyroid problemsGCST9047527643.17
15Rheumatoid arthritisFING0000126742.61
16Rheumatoid arthritis (PheCode 714.1)GCST9047623042.18
17Autoimmune diseases excluding thyroid diseasesFING0000013242.07
18HyperthyroidismGCST9046813641.90
19Autoimmune hyperthyroidismFING0000013441.43
20Second line medication for Crohn's diseaseFING0000128440.81
21Hypothyroidism, strict autoimmuneFING0000065640.66
22Papulosquamous disordersFING0000114440.12
23Graves' diseaseGCST9001862740.07
24Disorders of the thyroid glandFING0000046339.90
25KLRB1 levelsGCST9046970939.60
26Psoriatic arthritisGCST9024395639.32
27Lymphocyte countGCST9001874239.25
28Type 1 diabetesGCST9000052939.07
29TNFRSF8 levelsGCST9047091538.90
30Rheumatoid arthritis and other inflammatory (PheCode 714)GCST9047622838.28
31CD5/TNFRSF9 ratioGCST9031386237.73
32Graves disease, strict definitionFING0000059237.71
33PAG1 levelsGCST9047014737.67
34Other (seronegative) rheumatoid arthritis, wideFING0000091737.42
35Myasthenia gravisGCST9009306136.60
36First line medication for Crohn's diseaseFING0000054436.08
37Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditionsUKBB0000051836.00
38Dissociative [conversion] disordersFING0000046835.84
39lymphocyte (absolute count, minimum, inv-norm transformed)GCST9047542935.70
40HSIL lesion of the cervix uteriFING0000062435.62
41Ceramide (d18:2/24:1) levelsGCST9002468435.62
42Takes medication for Thyroid problems?GCST9047527735.55
43Atopic/contact dermatitis due to other or unspecified (PheCode 939)GCST9047628935.45
44Mean reticulocyte volumeGCST9002597535.24
45Treatment/medication code - levothyroxine sodium | MedicationsUKBB0000084935.17
46Non-cancer illness code, self-reported - eczema/dermatitis | Medical conditionsUKBB0000050935.09
47SKAP1 levelsGCST9047064534.96
48Eosinophil countGCST9002598734.82
49Ceramide (d18:2/22:0) levelsGCST9002468234.79
50CRTAM/FCRL6 ratioGCST9031427434.59
51lymphocyte (absolute count, mean, inv-norm transformed)GCST9047542634.36
52CD8 on Effector Memory CD8+ T cellGCST9000205634.19
53ITGAL levelsGCST9046963734.17
54Blood cell traits latent factor 20 (red cell)GCST9055926233.67
55HSIL lesion of the cervix uteri, vagina or vulvaFING0000062533.32
56Seropositive rheumatoid arthritis, wideFING0000129833.18
57Monoclonal gammopathy of undetermined significanceGCST9062474533.13
58CD48/CRTAM ratioGCST9031383933.05
59Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditionsUKBB0000010032.98
60PolyarthropathiesFING0000118032.95
61T1 FreeSurfer aseg Right-choroid-plexusGCST9038417032.89
62Lymphocyte countGCST9000231732.84
63Dermatitis and eczemaFING0000040232.62
64Lymphocyte countGCST9002598432.30
65Hypothyroidism | endocrine/metabolicUKBB0000033532.30
66Right-hemisphere dorsal attention network to amygdala white-matter structural connectivityGCST9030281132.28
67Crohn disease (strict definition, require KELA, min 2 HDR)FING0000036632.18
68Psoriasis vulgarisFING0000122432.02
69Mean corpuscular hemoglobin concentrationGCST9000239131.85
70SnoringGCST00976231.55
71Mean corpuscular hemoglobin concentrationGCST9001874531.42
72Treatment or medication use - insulin product (UKB data field 20003_1140883066)GCST9004222631.32
73Late-onset myasthenia gravisGCST9009346631.16
74CALCOCO1/TJAP1 ratioGCST9031361131.14
75Hypothyroidism NOS | endocrine/metabolicUKBB0000033631.14
76Other hypothyroidism | Disorders of thyroid glandUKBB0000061131.08
77Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044)GCST9004253531.04
78HypothyroidismGCST9020416731.00
79CD160/KLRB1 ratioGCST9031373130.81
80MAVS/TBL1X ratioGCST9031539930.77
81lymphocyte (fraction, minimum, inv-norm transformed)GCST9047543830.71
82Mouth/teeth dental problems - None of the above | MouthUKBB0000048930.66
83Age hay fever, rhinitis or eczema diagnosed | Medical conditionsUKBB0000001530.58
84Psoriasis vulgaris (PheCode 696.41)GCST9047619030.53
85FCRL6 levelsGCST9046920930.47
86Type 1 diabetesGCST9001402330.42
87Mean corpuscular hemoglobin concentrationGCST9000232830.39
88Rash and other nonspecific skin eruption (PheCode 687.1)GCST9047616730.20
89HEXIM1/TBL1X ratioGCST9031505330.20
90Type1 diabetes, definitions combined, early onsetFING0000138429.94
91HypothyroidismGCST9031932029.94
92DTI TBSS L2 External capsule LGCST9038450929.72
93Psoriasis (PheCode 696.4)GCST9047618729.71
94HLAE/IL15 ratioGCST9031506129.69
95HypothyroidismGCST9046813829.68
96IL15/IL18BP ratioGCST9031514829.34
97Autoimmune diseasesFING0000013129.25
98CDSN/WFDC12 ratioGCST9031399929.25
99Mean corpuscular haemoglobin concentration | Blood countUKBB0000044829.15
100IL2RA levelsGCST9046958529.08
101PAFAH1B3 levelsGCST9047014529.01
102Crohn's disease NASFING0000036728.49
103lymphocyte (absolute count, maximum, inv-norm transformed)GCST9047542328.41
104Right-hemisphere somatomotor network to amygdala white-matter structural connectivityGCST9030279928.36
105GZMH levelsGCST9046942528.06
106Graves' disease (PheCode 242.1)GCST9047564427.86
107Lymphocyte count | Blood countUKBB0000041127.67
108ThyrotoxicosisFING0000136027.61
109Asthma (childhood onset)GCST00780027.60
110Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24)GCST9030935827.44
111Prescriptions - levothyroxine | thyroid hormoneUKBB0000068727.38
112Prescriptions - thyroid hormone | hormoneUKBB0000070527.38
113IL15 levelsGCST9046955627.07
114Mean corpuscular hemoglobin concentrationGCST9000232927.07
115Lymphocyte countGCST00462727.06
116Nasal polypFING0000085827.00
117CRTAM/VCAM1 ratioGCST9031428126.86
118Paraproteinemia (PheCode 270.32)GCST9047571026.79
119Primary biliary cholangitisGCST9006144026.45
120Vanillactate levelsGCST9019997826.25
121CC2D1A/STAMBP ratioGCST9031366426.15
122Lymphocyte count (UKB data field 30120)GCST9046808226.10
123PDCD1 levelsGCST9047018126.09
124T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 78)GCST9032064126.08
125Coeliac diseaseGCST9046812025.96
126Disorders of orbitFING0000044925.84
127Rheumatoid arthritisGCST9013222325.83
128Allergic disease (asthma, hay fever or eczema)GCST00503825.75
129Regional enteritis (PheCode 555.1)GCST9047606625.72
130PneumoniaGCST9001868125.64
131Lymphoid neoplasmsGCST9062474325.49
132Margaroylcarnitine (C17) levelsGCST9019992925.48
133Thyrotoxicosis with diffuse goitreFING0000136125.47
134Type 1 diabetesGCST9001379125.42
135CXCL9 levelsGCST9046893525.30
136Symptoms concerning nutrition, metabolism, and development (PheCode 1002)GCST9047555625.15
137Psoriasis and related disorder (PheCode 696)GCST9047618625.13
138Mosaic chromosomal alteration of the X chromosomeGCST9016528725.08
139T1 FreeSurfer aseg MaskVol-to-eTIVGCST9038419224.80
140Eosinophill percentage (UKB data field 30210)GCST9046806924.55
141Thyroid peroxidase antibody positivity with euthyroid in pregnancyGCST9043520324.32
142DAPP1/ITGB1BP2 ratioGCST9031438824.02
143CD244/CRTAM ratioGCST9031376323.91
144Handedness (chirality/laterality) - Left-handed | Early life factorsUKBB0000030223.79
145Type 1 diabetes, definitions combinedFING0000138023.78
146Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditionsUKBB0000010123.74
147DermatitisFING0000040123.71
148TIGIT levelsGCST9047086523.59
149Lymphocyte countGCST9000238823.59
150Dermatomycosis (PheCode 110.2)GCST9047556523.23
151Multiple sclerosisGCST9047583323.16
152Neutrophil percentage of granulocytesGCST00462323.08
153Seronegative rheumatoid arthritisFING0000129623.05
154EczemaGCST9046812623.03
155Avoided activities or situations because of previous stressful experience in past month | Traumatic eventsUKBB0000008323.01
156Hypothyroidism, drug reimbursementFING0000065522.91
157Lymphocyte countGCST9000231622.84
158Rheumatoid arthritisGCST9001869022.79
159HippSubfield lh volume GC-ML-DG-headGCST9000267922.79
160mean corpuscular volume (MCV, minimum, inv-norm transformed)GCST9047547422.78
161Eosinophill percentage | Blood countUKBB0000020722.74
162eosinophil (fraction, minimum, inv-norm transformed)GCST9047530322.68
163Eosinophil percentage of white cellsGCST00460022.65
164ATP5IF1/METAP1D ratioGCST9031339122.47
165Mean corpuscular haemoglobin concentration (UKB data field 30060)GCST9046808522.41
166Average total household income before tax | HouseholdUKBB0000008122.38
167Eosinophil percentage of granulocytesGCST00461722.28
168GZMA/GZMH ratioGCST9031500822.06
169IL2RA/NCR1 ratioGCST9031516122.05
170rfMRI connectivity (ICA100 edge 605)GCST9000545822.04
171Left-hemisphere visual network to left-hemisphere visual network white-matter structural connectivityGCST9030264821.94
172EDAR/LAT2 ratioGCST9031458221.93
173CRTAM/TNFRSF9 ratioGCST9031428021.64
174Dementia due to Parkinson's disease (more control exclusions)FING0000039221.53
175Primary biliary cholangitisGCST00312921.52
176Chronic obstructive pulmonary disease in current smokersGCST9001659321.44
177Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448)GCST9013296821.40
178Noninfective enteritis and colitisFING0000088121.36
179PPP1R2/TBL1X ratioGCST9031572021.22
180mean corpuscular volume (MCV, mean, inv-norm transformed)GCST9047547021.19
181mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST9047545021.03
182mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed)GCST9047544221.02
183SH2B3/TBL1X ratioGCST9031584120.99
184Eosinophill count | Blood countUKBB0000020620.98
185Suggestive for eosinophilic asthmaFING0000134420.91
186lymphocyte (fraction, mean, inv-norm transformed)GCST9047543520.90
187Crohn's disease of small intestineFING0000036920.87
188CRTAM/LY9 ratioGCST9031427820.85
189IDP dMRI ProbtrackX L1 ifo rGCST9000425920.79
190GNLY levelsGCST9046937220.74
191Inflammatory bowel disease, strict (require KELA)FING0000067520.69
192ANP32B levelsGCST9024017620.68
193mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST9047544620.66
194MZB1 levelsGCST9046998720.63
195Follicular lymphoma, hilmo (controls excluding all cancers)FING0000054820.52
196Eosinophil percentage of white cellsGCST9000238220.36
197IL1RL1 levelsGCST9046957420.31
198Atopic dermatitisFING0000012520.21
199Blood cell traits latent factor 23 (white cell)GCST9055926520.08
200IL15/NCR1 ratioGCST9031515020.00
201mean corpuscular volume (MCV, maximum, inv-norm transformed)GCST9047546619.98
202Rheumatoid arthritisGCST9013222419.81
203Thyroid peroxidase antibody levels in pregnancyGCST9043520119.78
204SIT1 levelsGCST9047064419.69
205Thyroid peroxidase antibody positivity in pregnancyGCST9043520219.65
206Eosinophill count (UKB data field 30150)GCST9046806819.56
207Mean reticulocyte volume | Blood countUKBB0000045119.53
208Rheumatoid arthritisGCST00067919.52
209eosinophil (fraction, mean, inv-norm transformed)GCST9047530019.45
210IDP dMRI TBSS L1 Posterior limb of internal capsule RGCST9000409319.39
211Early-onset myasthenia gravisGCST9009346519.28
212Solitary pulmonary nodule (PheCode 514.2)GCST9047604419.12
213Medication use (drugs affecting bone structure and mineralization)GCST9001877319.09
214Lichen ruber planus, wide definition including periferal and oral lichen planusFING0000072219.09
215eosinophil (fraction, maximum, inv-norm transformed)GCST9047529719.08
216Congenital malformations of genital organsFING0000033319.01
217Taking other prescription medications | MedicationUKBB0000081318.92
218Right-hemisphere visual network to right-hemisphere dorsal attention network white-matter structural connectivityGCST9030277618.83
219Pollen allergyFING0000117618.73
220IDP dMRI TBSS ISOVF Anterior corona radiata LGCST9000450018.68
221ZNF830 levelsGCST9047110218.65
222Asthma (adult onset)GCST00779918.59
223Poisoning by antibiotics | injuries & poisoningsUKBB0000065318.51
224Lymphoid neoplasms (P-cell phenocluster)GCST9062473718.50
225Octadecenedioylcarnitine (C18:1-DC) levelsGCST9019997018.46
226Mental and behavioural disorders due to use of other stimulants, including caffeineFING0000081118.32
227Ulcerative colitisGCST9044679518.28
228Lymphangioleiomyomatosis (sporadic)GCST00831118.24
229NHLRC3 levelsGCST9047004618.19
230CD244/FCRL6 ratioGCST9031376518.16
231Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health statusUKBB0000064118.12
232Mean sphered cell volume | Blood countUKBB0000045218.12
233Respiratory disease (confirmatory factor analysis Factor 11)GCST9030934518.11
234Childhood asthma (age<16) (more control exclusions)FING0000027018.09
235Lymphoid neoplasms (drug group 1 phenocluster)GCST9062474018.04
236Cervicalgia (PheCode 761)GCST9047626718.02
237LTA levelsGCST9046981318.02
238Infective dermatitisFING0000067317.99
239FCRL5/LY96 ratioGCST9031480317.92
240FUT8/TNFSF14 ratioGCST9031489517.90
241Other disorders of glucose regulation and pancreatic internal secretionFING0000102817.89
242PsoriasisFING0000122217.79
243PRG3 levelsGCST9047032317.68
244TFRC levelsGCST9047084017.57
245CLC levelsGCST9046876217.41
246Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complicationsGCST9009311317.41
247Lichen sclerosus et atrophicusFING0000072317.37
248ChalazionFING0000026717.32
249SarcoidosisGCST9050348317.26
250N-acetyl-1-methylhistidine levelsGCST9020069017.08
251Congenital malformations of ovaries, fallopian tubes and broad ligamentsFING0000033717.06
252CXCL16 levelsGCST9046892817.05
253Left-hemisphere dorsal attention network to amygdala white-matter structural connectivityGCST9030270617.02
254Chronic nephritic syndromeFING0000029517.02
255CD69/EDAR ratioGCST9031387516.97
256Leisure/social activities - None of the above | Social supportUKBB0000039916.90
257Lymphocyte percentage | Blood countUKBB0000041216.85
258TPSAB1 levelsGCST9047095116.77
259Bread type: Wholemeal or wholegrain (UKB data field 1448_3)GCST9013296616.76
260PLAT levelsGCST9047025016.70
261Inflammatory bowel diseaseGCST9043218216.69
262LY6D/WFDC12 ratioGCST9031534616.67
263Chronic sinusitisFING0000029816.66
264PsoriasisGCST9046814716.66
265Eosinophil countGCST9000229816.59
266Chromatiales abundance in stoolGCST9003231816.57
267Thyrotoxicosis with or without goiter (PheCode 242)GCST9047564316.56
268Eosinophil countGCST9000238116.48
269Lymphoid neoplasms (B-cell phenocluster)GCST9062473616.44
270Citrulline levelsGCST9020040316.42
271Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T1ECGA00000116.42
272ICD10 O60: Preterm labor and deliveryGCST9045424216.33
273Principal component-derived dietary pattern 28GCST9013303316.33
274IDP T1 SIENAX grey normalised volumeGCST9000243016.30
275Coeliac diseaseFING0000031216.13
276EPO/TFRC ratioGCST9031468416.09
277MAP2K6/TBL1X ratioGCST9031537816.03
278Allergy/adverse effect of penicillin | injuries & poisoningsUKBB0000002816.02
279CPXM1/HBEGF ratioGCST9031421916.01
280IL5RA/TNFRSF13B ratioGCST9031516415.96
281GZMB/IL15 ratioGCST9031501515.95
282ATP5IF1/LYN ratioGCST9031338915.91
283Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)GCST9013222715.90
284CD6 levelsGCST9046864415.78
285Left-hemisphere control network to amygdala white-matter structural connectivityGCST9030275715.73
286Chronic lymphocytic leukemiaGCST9062473815.71
287Lymphocyte percentage of white cellsGCST9000238915.70
288Cancer of urinary organs (incl. kidney and bladder) (PheCode 189)GCST9047559315.67
289Frailty (Factor 4 - Metabolic Problems)GCST9062405015.66
290Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditionsUKBB0000051315.64
291Lichen simplex chronicus and prurigoFING0000072515.64
292CRTAM/ICAM3 ratioGCST9031427615.56
293Eosinophil countGCST00460615.52
294Asthma | respiratoryUKBB0000005415.51
295Mean sphered cell volume (UKB data field 30270)GCST9046808915.50
296Muscular dystrophyFING0000084815.50
297CD160/CXCL16 ratioGCST9031372815.48
298Right-hemisphere control network to amygdala white-matter structural connectivityGCST9030284115.42
299Lymphocyte percentage (UKB data field 30180)GCST9046808315.37
300AsthmaGCST01004215.35
301EDAR/ERBIN ratioGCST9031457515.27
302Uterine fibroidsGCST9046815415.24
303Mean reticulocyte volume (UKB data field 30260)GCST9046808815.24
304Lymphocyte percentage of white cellsGCST00463215.04
305Ulcerative colitisGCST00413315.01
306CD8A levelsGCST9046865514.98
307Mean spheric corpuscular volumeGCST9000239714.97
308Asthma | Chronic lower respiratory diseasesUKBB0000005314.97
309Other arthritis (FG)FING0000096414.95
310Bread type - White | DietUKBB0000010614.91
311SUGT1/TBL1X ratioGCST9031589714.78
312AsthmaGCST9046811214.67
313KLRF1 levelsGCST9046971214.64
314lymphocyte (fraction, maximum, inv-norm transformed)GCST9047543214.63
315Cereal intake | DietUKBB0000012114.51
316Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditionsUKBB0000009814.41
317PDCD1/TNFRSF8 ratioGCST9031561014.32
318MS-disease / Multiple SclerosisFING0000083914.31
319Handedness (chirality/laterality) - Right-handed | Early life factorsUKBB0000030314.30
320IDP T1 SIENAX grey unnormalised volumeGCST9000243114.27
321Bread type: White (UKB data field 1448_1)GCST9013296414.20
322GZMA/GZMB ratioGCST9031500714.19
323Open biteFING0000090314.18
324Vitamin B12 deficiency anaemiaFING0000144114.13
325Sum eosinophil basophil countsGCST00462414.13
326SH2D1A levelsGCST9047061714.12
327CAPG levelsGCST9046853714.11
328Bread type: White vs wholemeal/wholegrain and brown (UKB data field 1448)GCST9013296714.10
329FCRL3 levelsGCST9046920714.09
330GOPC/IRAK4 ratioGCST9031495414.06
331IL22 levelsGCST9046958214.03
332Atopic dermatitisGCST9002716114.03
333SarcoidosisFING0000127513.91
334Internal derangement of knee | injuries & poisoningsUKBB0000036813.88
335EDAR/SNAP23 ratioGCST9031458713.82
336Mean reticulocyte volumeGCST9000239613.81
337Atopic dermatitisGCST9001856413.81
338Dermatitis due to ingested foodFING0000040313.81
339Lymphoid neoplasms (somatic mutation group 2 phenocluster)GCST9062475013.75
340Prescriptions - antispasmodicUKBB0000066613.72
341EBAG9/FKBP5 ratioGCST9031456413.69
342Other diseases of the respiratory systemFING0000101113.66
343PPP1R14D levelsGCST9047030313.62
344Biological Sibling: AsthmaGCST9047637213.61
345CXCL16/NOTCH1 ratioGCST9031433913.61
346red cell diameter width (RDW, minimum, inv-norm transformed)GCST9047636313.60
347IDP dMRI TBSS OD Posterior limb of internal capsule RGCST9000442013.55
348GZMB levelsGCST9046942413.55
349Dried fruit likingGCST9009475613.51
350Mean corpuscular volumeGCST9000239213.50
351TSC1 levelsGCST9047097213.45
352CD79B/TNFRSF4 ratioGCST9031390313.41
353Non-small cell lung cancer, squamous, excluding all cancers (controls excluding all cancers)FING0000087713.39
354ITGB1BP2/USP8 ratioGCST9031522313.37
355Mean corpuscular volume (UKB data field 30040)GCST9046808613.37
356Bread type - Wholemeal or wholegrain | DietUKBB0000010713.32
357Cancer of bronchus; lung (PheCode 165.1)GCST9047557313.29
358CALCOCO1/VPS53 ratioGCST9031361213.29
359Cerebrospinal fluid methylmalonate (MMA) levelsGCST9031824313.29
360CRTAM levelsGCST9046887113.27
361NCR1 levelsGCST9047000913.25
362Eosinophil countGCST9000229913.24
363VSTM2B levelsGCST9047105613.23
364Operation code - tonsillectomy +/- adenoids | OperationsUKBB0000056713.21
365Right-hemisphere control network to right-hemisphere control network white-matter structural connectivityGCST9030283413.13
366Snoring | SleepUKBB0000078413.12
367CD27/NBL1 ratioGCST9031377413.12
368NECTIN2/NPDC1 ratioGCST9031552813.06
369CXCL16 levelsGCST9024052413.04
370TP53BP1 levelsGCST9047093613.02
371GRAP2/SRC ratioGCST9031498913.01
372Mean corpuscular volume | Blood countUKBB0000044913.01
373Lymphoid leukemia, chronic (PheCode 204.12)GCST9047561313.00
374ERBB4/F3 ratioGCST9031469012.99
375Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35)GCST9030936912.99
376GZMA/LTA ratioGCST9031501212.91
377PRG2 levelsGCST9047032212.91
378Carboplatin drug response (IC50)GCST9001178312.89
379CALCOCO1/PDLIM7 ratioGCST9031360712.89
380Medication use (immunosuppressants)GCST9001877112.86
381Blood cell traits latent factor 9 (white cell)GCST9055925112.85
382Eosinophil countGCST9001873312.84
383Left-hemisphere visual network to left-hemisphere control network white-matter structural connectivityGCST9030265312.79
384DTI TBSS L1 Cingulum cingulate gyrus LGCST9038446312.77
385T1 CAT volume L VIIIaGCST9038412712.75
386Pulmonary fibrosisGCST9001868812.74
387Psoriatic arthropathiesFING0000122512.72
388CD160 levelsGCST9046859912.71
389CRTAM/GZMA ratioGCST9031427512.65
390eosinophil (absolute count, minimum, inv-norm transformed)GCST9047529412.64
391Rheumatoid arthritis | musculoskeletalUKBB0000075712.64
392DNAJC21 levelsGCST9046901612.63
393Asthma-related infectionsFING0000011812.60
394EndometriosisGCST9001861912.57
395THBS2 levelsGCST9047085412.56
396CCL8 levelsGCST9042234612.50
397Cancer within the respiratory system (PheCode 165)GCST9047557112.49
398TXNL1 levelsGCST9047099312.49
399NME3 levelsGCST9047005512.47
400UCMA levelsGCST9024328512.47
401Mouth/teeth dental problems - Bleeding gums | MouthUKBB0000048512.47
402EDAR/TACC3 ratioGCST9031458912.43
403CC2D1A/STIP1 ratioGCST9031366512.43
404AXIN1/ITGB1BP2 ratioGCST9031341212.43
405Low hand grip strength (60 years and older) (EWGSOP)GCST9000752712.42
406Other specified disorders of external earFING0000110412.42
407Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41)GCST9066848512.42
408Low hand grip strength (60 years and older) (FNIH)GCST9000752912.36
409ITGB1BP2/PTPN6 ratioGCST9031521812.35
410CD5/IL16 ratioGCST9031386112.35
411Types of physical activity in last 4 weeks - None of the above | Physical activityUKBB0000087212.31
412Other and/or unspecified nontoxic goitreFING0000095812.23
413Neoplasm of uncertain behavior (PheCode 199)GCST9047560612.23
414CD27 levelsGCST9046861512.20
415Asthma/COPD (KELA code 203)FING0000012112.20
416SLAMF8 levelsGCST9047065212.19
417AsthmaGCST9047525912.19
418CataractsGCST9001859412.19
419eosinophil (absolute count, maximum, inv-norm transformed)GCST9047528812.18
420MelanomaGCST9001180912.17
421Phlebitis and thrombophlebitis of lower extremities (PheCode 451.2)GCST9047600412.17
422IDP T1 SIENAX brain-normalised volumeGCST9000243412.15
423IL10 levelsGCST9046954612.11
424Sicca syndrome [Sjögren]FING0000130412.11
425HAVCR2 levelsGCST9042151512.11
426All pneumoniaeFING0000006512.08
427DTI TBSS L3 Cingulum hippocampus RGCST9038456012.06
428Chronic lower respiratory diseasesFING0000029012.03
429red cell diameter width (RDW, maximum, inv-norm transformed)GCST9047635512.03
430SIGLEC1/SSC5D ratioGCST9031584412.02
431BCR/FOXO1 ratioGCST9031349012.01
432TNFRSF17 levelsGCST9047090811.99
433ICD10 N97.8: Female infertility of other originGCST9045422511.97
434Basal cell carcinoma (MTAG)GCST9013741111.95
435Mineral and other dietary supplements - Glucosamine | MedicationUKBB0000047311.95
436DTI autoptx FA slf l tractGCST9038513311.95
437Spleen iron concentrationGCST9010183111.94
438Mean corpuscular volumeGCST00460211.94
439IL32 levelsGCST9046959111.94
440Uterine fibroidsGCST9046195811.92
441X-21285 levelsGCST9020057611.91
442Principal component-derived dietary pattern 42GCST9013304711.80
443PsoriasisGCST9001901611.80
444CDC27 levelsGCST9046866411.80
445B2M levelsGCST9046840911.78
446eosinophil (absolute count, mean, inv-norm transformed)GCST9047529111.78
447CXCL5/PLXNA4 ratioGCST9031435111.74
448Other obstetric traumaFING0000108211.71
449SH3GLB2 levelsGCST9047062111.61
450Raynauds phenomenon diseaseGCST9027171311.58
451Lung cancerGCST00474811.57
452Other diseases of upper respiratory tractFING0000101211.50
453CRTAM/PDCD1 ratioGCST9031427911.48
454LGALS3BP levelsGCST9046976011.44
455Non-cancer illness code, self-reported - asthma | Medical conditionsUKBB0000050611.42
456Mean corpuscular hemoglobin concentrationGCST00460511.42
457Interpolated Year when non-cancer illness first diagnosed | Medical conditionsUKBB0000037111.38
458Parkinson's diseaseFING0000115011.29
459APP/HBEGF ratioGCST9031332411.28
460MAVS/MED18 ratioGCST9031538911.26
461F5 levelsGCST9044646611.20
462Skin cancerGCST9047518911.19
463Doctor diagnosed hayfever or allergic rhinitis | Medical informationUKBB0000019211.16
464Asthma-related acute respiratory infectionsFING0000011711.13
465Systemic lupus erythematosusGCST9001186611.12
466MED18/TBL1X ratioGCST9031541511.12
467CCL19 levelsGCST9046857111.11
468Lung adenocarcinomaGCST00474411.10
469DTI TBSS L2 External capsule RGCST9038450811.09
470Ever SmokerFING0000052211.07
471DTI TBSS L2 Superior longitudinal fasciculus LGCST9038451711.06
472TNFRSF9 levelsGCST9047091611.04
473Ceramide (d18:2/22:0) levelsGCST9002405411.03
474Treatment/medication code - ventolin 100micrograms inhaler | MedicationsUKBB0000086011.01
475SUMF1 levelsGCST9047078310.99
476CRACR2A/LBR ratioGCST9031422810.98
477CD48/FCRL6 ratioGCST9031384010.94
478Dizziness and giddiness (Light-headedness and vertigo) (PheCode 386.9)GCST9047590810.87
479Asthma (only as main-diagnosis) (more control exclusions)FING0000011410.78
480TRAF2/WWP2 ratioGCST9031594310.76
481IFNG levelsGCST9046951510.76
482Melanomas of skin, dx or hx (PheCode 172.1)GCST9047557710.75
483HMBS/PKLR ratioGCST9031506310.72
484Diseases of middle ear and mastoidFING0000042710.70
485Takes medication for Skin condition (ex. Eczema, Psoriasis)?GCST9047527510.68
486UGDH levelsGCST9047100610.67
487ITGB1BP2/TIA1 ratioGCST9031522210.66
488GZMH/KLRD1 ratioGCST9031501610.63
489Lung cancerGCST9001865510.63
490T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 97)GCST9032091610.60
491AsthmaGCST9047602410.55
492Basal cell carcinoma (PheCode 172.21)GCST9047558210.54
493AHSP/BLVRB ratioGCST9031321410.45
494Other circulatory problemGCST9047521710.44
495Asthma (more control exclusions)FING0000011310.44
496BAG6/BMP6 ratioGCST9031345010.32
497Mouth/teeth dental problems - Mouth ulcers | MouthUKBB0000048810.29
498Neuroendocrine tumor and carcinoma of pancreas, excluding all cancers (controls excluding all cancers)FING0000086410.18
499FCRL2/SEMA7A ratioGCST9031480010.11
500Stearoylcarnitine (C18) levelsGCST9019974310.10
501HayfeverGCST9046813110.09
502Long-standing illness, disability or infirmity | General healthUKBB0000040910.09
503CD27/TGFBR2 ratioGCST9031377610.08
504EDAR/IPCEF1 ratioGCST9031457810.05
505IL16 levelsGCST9046955710.02
5063-hydroxydecanoate metabolite levelGCST9061547210.01
507Mean corpuscular hemoglobinGCST9000239010.00
508CSNK1D levelsGCST9046888810.00
509IDP T1 SIENAX brain-unnormalised volumeGCST900024359.99
510Operation code - spine or back surgery | OperationsUKBB000005659.98
511Multiple myeloma or monoclonal gammopathy of undetermined significanceGCST906247469.98
512DBNL/EDAR ratioGCST903144169.97
513SRP14 levelsGCST904707429.95
514AsthmaGCST900143259.95
515Malignant neoplasm, excluding all cancers (controls excluding all cancers)FING000007809.93
516Tobacco use disorder | mental disordersUKBB000008249.91
517Strenuous sports or other exercisesGCST0061009.91
518CALCOCO1/METAP2 ratioGCST903136069.88
519Other disorders of amino-acid metabolismFING000010149.85
520IFI30 levelsGCST904695099.83
521RBFOX3 levelsGCST904704329.81
522DTI autoptx L2 slf l tractGCST903851879.75
523Right-hemisphere visual network to amygdala white-matter structural connectivityGCST903027869.74
524BCR/ITGB1BP2 ratioGCST903134949.74
525Age at onset of walkingGCST906510789.68
526BLNK levelsGCST904684489.66
527Skin cancerGCST904755759.65
528mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed)GCST904754549.65
529Hernia abdominopelvic cavityGCST900860879.59
530KLK8/WFDC12 ratioGCST903152599.56
531CEACAM8/PGLYRP1 ratioGCST903140039.55
532RAP1A levelsGCST904704259.53
533Leisure/social activities - Other group activity | Social supportUKBB000004009.52
534Volume of right cortical nucleusGCST904750339.49
535CD74/NPDC1 ratioGCST903138959.45
536DTI autoptx L1 atr l tractGCST903851419.44
537mean corpuscular hemoglobin concentration (MCHC, minimum, inv-norm transformed)GCST904754629.41
538Operation code - wisdom teeth surgery | OperationsUKBB000005699.36
539STX6 levelsGCST904707749.35
540IGFBP6/MFAP5 ratioGCST903151359.33
541Illnesses of father - Lung cancer | Family historyUKBB000003449.29
542Nonspecific chest pain | circulatory systemUKBB000005279.29
543IridocyclitisFING000006969.29
544CXCL10 levelsGCST904689239.28
545Erythematosquamous dermatosis (PheCode 690)GCST904761709.26
546HippSubfield lh volume CA4-headGCST900026829.25
547FCRL5/ICAM3 ratioGCST903148029.22
548CA1/HMBS ratioGCST903135739.22
549Basal cell carcinomaGCST900134109.21
550MAPRE3 levelsGCST904698599.15
551Seborrheic dermatitis (PheCode 690.1)GCST904761719.07
552Late-onset myasthenia gravisGCST904321589.07
553ITGB1BP2/WASF1 ratioGCST903152249.06
554UNC5D levelsGCST904710109.04
555Mean corpuscular haemoglobin | Blood countUKBB000004479.02
556INSL5 levelsGCST904696229.01
557Wheeze or whistling in the chest in last year | BreathingUKBB000009128.97
558CD27/TNFRSF9 ratioGCST903137788.96
559SnoringGCST0097608.95
560aparc-a2009s rh volume G-occipital-supGCST900030188.93
561HBEGF/PDGFA ratioGCST903150338.92
562Mean corpuscular haemoglobin (UKB data field 30050)GCST904680848.92
563Irregular menstrual cycle/bleeding | genitourinaryUKBB000003798.91
564Crohn's diseaseGCST0041328.91
565RHOC/TBCB ratioGCST903157748.89
566ADAM12 levelsGCST904682168.89
567Never eat wheat vs no wheat restrictions (UKB data field 6144)GCST901329328.89
568Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T2ECGA0000028.86
569Glycated hemoglobin levelsGCST900022448.84
570ITGB7 levelsGCST904696478.84
571MINPP1 levelsGCST902419788.81
572Cerebral aneurysm, nonrupturedFING000002638.80
573TNFRSF13B levelsGCST904709058.79
574N-acetylmethionine levelsGCST902002898.77
575Suppurative and unspecified otitis mediaFING000013468.75
576CD7 levelsGCST904686498.69
577TNF/TNFRSF1B ratioGCST903159428.66
578Other non-epithelial cancer of skin (PheCode 172.2)GCST904755808.64
579IDP T1 SIENAX peripheral grey normalised volumeGCST900024268.61
580BMP7 levelsGCST900881578.59
581ATF6 levelsGCST902408168.59
582Left-hemisphere somatomotor network to left-hemisphere control network white-matter structural connectivityGCST903026738.58
583Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systemsUKBB000006258.57
584SNAP23/TBL1X ratioGCST903158568.56
585Estradiol levelsGCST900121058.54
586Systemic connective tissue disordersFING000013508.53
587GALNT10/SEMA7A ratioGCST903149158.53
588DTI autoptx MD cgc l tractGCST903852248.51
589Crohn's diseaseGCST904467938.50
590Immature reticulocyte fraction | Blood countUKBB000003558.48
591Thoracic or lumbosacral neuritis or radiculitis, unspecified (PheCode 763)GCST904762688.48
592IDP dMRI ProbtrackX MD ptr rGCST900042398.42
593FAM3B/FUT3_FUT5 ratioGCST903147778.40
594INPP5J levelsGCST904696188.35
595Poultry consumptionGCST901329968.35
596Cancer of bladder (PheCode 189.2)GCST904755988.34
597Takes medication for Chronic lung diseases including COPD, Emphysema and Bronchitis?GCST904752738.31
598Red cell distribution widthGCST900259888.30
599CASP10 levelsGCST904685428.30
600mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST904754488.27
601Mental and behavioural disorders due to use of tobacco | Mental and behavioural disorders due to psychoactive substance useUKBB000004608.27
602FCRL1/TCL1A ratioGCST903147958.24
603Blood cell traits latent factor 10 (platelet)GCST905592528.23
604IDP T1 FAST ROIs L cerebellum XGCST900025878.22
605EDAR/F2R ratioGCST903145778.20
606Job involves shift work | EmploymentUKBB000003858.17
607BleedingFING000002198.15
608Pain type(s) experienced in last month - Pain all over the body | PainUKBB000006328.14
609FCRL6/GZMA ratioGCST903148068.11
610Ulcerative colitis (strict definition, require KELA, min 2 HDR)FING000013888.10
611COX5B/GFER ratioGCST903142008.09
612DTI TBSS L1 Anterior corona radiata RGCST903844508.08
613FCER1A levelsGCST904691988.07
614CAPS levelsGCST904685398.07
615OSMR levelsGCST904701328.07
616LTA4H levelsGCST904698128.03
617Type of accommodation lived in - A flat, maisonette or apartment | HouseholdUKBB000008687.99
618Mean corpuscular hemoglobinGCST0046307.99
619CA1/CA3 ratioGCST903135727.96
620Pain in joint (PheCode 745)GCST904762627.95
621ExotropiaGCST905727377.95
622mean corpuscular hemoglobin concentration (MCHC, mean, inv-norm transformed)GCST904754587.94
623Disorders of plasma protein metabolism (PheCode 270.3)GCST904757097.94
624Temporomandibular joint disorders, including avohilmoFING000013557.93
625Urine N-acetylglutamate levels in chronic kidney diseaseGCST902655697.91
626Avocado likingGCST900946947.90
627Usual side of head for mobile phone use - Left | Electronic device useUKBB000008897.88
628PDCD1/TNFRSF9 ratioGCST903156117.87
629LMNB2 levelsGCST904697827.86
630Primary biliary cholangitis (PBC)FING000012117.86
631BIN2/FYB1 ratioGCST903135057.85
632Papillary adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers)FING000011437.84
633Left-hemisphere limbic network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027317.83
634IL15/KLRD1 ratioGCST903151497.81
635Hair colour (natural, before greying): Red (UKB data field 1747_2)GCST900418377.81
636EDAR/ITGB1BP2 ratioGCST903145807.81
637Subclinical hypothyroidism in pregnancyGCST904351977.81
638Cough (PheCode 512.8)GCST904760417.80
639Celiac disease (PheCode 557.1)GCST900441587.80
640TCL1A/TNFRSF13C ratioGCST903159127.77
641Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditionsUKBB000003697.76
642Red blood cell (erythrocyte) distribution width | Blood countUKBB000007487.75
643Milk type used: Soy milk vs never have milk (UKB data field 1418)GCST901329437.74
644KDM3A levelsGCST904696717.74
645Occupational attainmentGCST901022537.74
646Influenza and pneumoniaFING000006797.71
647Erythematous conditions (PheCode 695)GCST904761777.71
648Never eat wheat vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144)GCST901329317.70
649PCOLCE levelsGCST904701757.68
650TNFRSF13B/TNFSF13B ratioGCST903159337.68
651aparc-a2009s rh area G-pariet-inf-AngularGCST900033957.67
652EBAG9/TGFB1 ratioGCST903145707.67
653Attendance/disability/mobility allowance - None of the above | Other sociodemographic factorsUKBB000000597.67
654Number in household | HouseholdUKBB000005307.62
655Principal component-derived dietary pattern 12GCST901330177.61
656MAP3K5/ZBTB16 ratioGCST903153807.60
657ADH4/SCLY ratioGCST903131957.60
658IDP dMRI TBSS FA Posterior limb of internal capsule RGCST900038957.59
659DTI TBSS MD Posterior limb of internal capsule LGCST903845917.57
660Glomerular disorders in diseases classified elsewhereFING000005827.56
661Nasal polyp | Other diseases of upper respiratory tractUKBB000004937.55
662Moderate-to-vigorous intensity physical activity during leisure timeGCST901043417.54
663aseg rh intensity Cerebellum-CortexGCST900037817.52
664DTI TBSS MD Body of corpus callosumGCST903845757.51
665CD27/DLL1 ratioGCST903137717.49
666CD101 levelsGCST904685967.47
667LBR/POLR2F ratioGCST903152977.46
668IDP T1 SIENAX peripheral grey unnormalised volumeGCST900024277.46
669Parental longevity (combined parental age at death)GCST0067027.46
670Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T20ECGA0000207.43
671CHMP1A/RHOC ratioGCST903140537.43
672PFKM levelsGCST906188027.43
673KYNU/SCLY ratioGCST903152657.39
674Qualifications - A levels/AS levels or equivalent | EducationUKBB000007277.37
675NPPB levelsGCST904700747.37
676Nasal polypsGCST904681437.36
677NCAN levelsGCST906185597.36
678PDCD1/TNFRSF4 ratioGCST903156097.35
679Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T228ECGU0002287.34
680Dried fruit consumptionGCST901329807.33
681DTI TBSS L3 Superior corona radiata LGCST903845497.32
682Prescriptions - tramadol | opioid analgesic,selective serotonin re-uptake inhibitor,norepinephrine re-uptake inhibitorUKBB000007067.31
683Prescriptions - opioid analgesic|selective serotonin re-uptake inhibitor|norepinephrine re-uptake inhibitorUKBB000006947.31
684TNFRSF11A levelsGCST902776447.30
685Acute upper respiratory infectionsFING000000347.29
686NeuroticismGCST0029207.28
687AXL/IL18BP ratioGCST903134207.25
688MAP3K5/MAVS ratioGCST903153797.21
689Time spent watching television (TV) | Physical activityUKBB000008217.21
690X-11550 levelsGCST902436487.21
691Seborrhoeic dermatitisFING000012827.19
692Chronic airway obstruction | respiratoryUKBB000001357.18
693How many years have you or did you smoke cigarettes? (inv-normal transformed)GCST904763907.13
694DTI autoptx L1 cst r tractGCST903851487.11
695DTI TBSS L1 Posterior thalamic radiation LGCST903844577.11
696Red cell distribution widthGCST900023697.10
697CCN2/HBEGF ratioGCST903137137.08
698Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T384ECGU0003847.07
699X-08402 levelsGCST902435387.06
700Red blood cell erythrocyte distribution width (UKB data field 30070)GCST904680997.06
701CRADD/HSPA1A ratioGCST903142397.06
702Qualifications - None of the above | EducationUKBB000007297.05
703NELL1 levelsGCST902424817.04
704Acute pancreatitisFING000000277.03
705EFNA4/TNFRSF9 ratioGCST903146067.03
706Red cell distribution widthGCST900024047.02
707Rosacea (PheCode 695.3)GCST904761787.00
708LifespanGCST905518867.00
709mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST904754446.99
710HBEGF/PLXNA4 ratioGCST903150366.98
711Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905023966.95
712FAM13A levelsGCST904691816.95
7132,3-dihydroxy-5-methylthio-4-pentenoate (dmtpa) levelsGCST902002336.94
714Mean platelet volume at deliveryGCST903022326.93
715CEP43/MPHOSPH8 ratioGCST903140196.93
716DTI TBSS MD Superior corona radiata LGCST903845976.91
717Principal component-derived dietary pattern 1GCST901330066.91
718SMOC2 levelsGCST904227736.91
719IGSF8/NECTIN2 ratioGCST903151406.90
720Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555)GCST904760656.89
721Types of physical activity in last 4 weeks - Other exercises (eg: swimming, cycling, keep fit, bowling) | Physical activityUKBB000008736.89
722All dysplastic lesions of the cervix uteriFING000000606.88
723ENO2/RWDD1 ratioGCST903146676.87
724SMPD3 levelsGCST904706856.87
725Hepatic cancerGCST900186386.86
726SDC4/WWP2 ratioGCST903158216.85
727BCL2 levelsGCST904684336.84
728Breast cancerGCST904298466.83
729REST UKBBICA NODEamps25 0016GCST903854996.82
730CD79B/FCRL1 ratioGCST903138996.81
731MCTS1 levelsGCST904698746.81
732NRSN1 levelsGCST902420626.80
733Carcinoma in situ of breast, intraductal (controls excluding all cancers)FING000002406.80
734Gestational age at birth (maternal effect)GCST902684196.79
735DTI autoptx L3 slf l tractGCST903852146.78
736CALCOCO1/CASP3 ratioGCST903135966.78
737Other arthrosisFING000009656.77
738Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T497ECGA0004976.77
739Aniseed likingGCST900946896.76
740Rhodanobacter abundance in stoolGCST900325366.72
741Parental longevity (father's age at death)GCST0067006.71
742COPD/asthma/ILD related infectionsFING000003536.69
743Type of accommodation lived in - A house or bungalow | HouseholdUKBB000008696.68
744Cervical cancerGCST900118166.67
745Primary sclerosing cholangitisGCST0040306.66
746Omega-3 fatty acids to total fatty acids percentageGCST905024606.66
747ARHGAP25/RNF41 ratioGCST903133456.66
748ThalamNuclei lh volume MDlGCST900027246.65
749IDP dMRI TBSS MD Posterior limb of internal capsule RGCST900040456.62
750CA3/HMBS ratioGCST903135846.60
751STX8 levelsGCST904707766.60
752Sphingomyelin_41:2_[M+H]1+ levelsGCST900603836.60
753Allergic rhinitisFING000000716.60
754Asthma, unspecified (mode)FING000001206.60
755Prostate cancerGCST900186856.59
756Active to sedentary transition probabilityGCST900614296.58
757N-acetyltaurine levelsGCST901999676.58
758Crohn's disease of large intestineFING000003686.57
759GZMA/TNFRSF8 ratioGCST903150146.56
760Smoking status (standard GWA)GCST902673026.56
761CDSN/LY6D ratioGCST903139976.55
762Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T21ECGA0000216.52
763Current SmokerFING000003716.51
764GDF15 levelsGCST904693216.51
765Ulcerative enterocolitisFING000013916.51
766EZR levelsGCST904691626.49
767CXCL5/MESD ratioGCST903143506.49
768Type 1 diabetesGCST904320666.48
769GBP4 levelsGCST904693136.47
770Neoplasm of uncertain behavior of skin (PheCode 173)GCST904755856.46
771Left-hemisphere salience/ventral attention network to amygdala white-matter structural connectivityGCST903027246.44
772Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T4ECGA0000046.43
773DiverticulitisGCST904681256.41
774GPLD1 levelsGCST900868906.40
775Basophil countGCST900187266.40
776Tooth agenesis EXCLUDE clefts and syndromesFING000013686.39
777Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T3ECGA0000036.38
778Disorders of eyelid, lacrimal system and orbitFING000004396.37
779ATXN10/CASP10 ratioGCST903133966.37
780DTI TBSS MD Anterior limb of internal capsule LGCST903845896.36
781Secondary hypothyroidism (PheCode 244.1)GCST904756496.35
782CD22/TCL1A ratioGCST903137606.34
783CA2/CA3 ratioGCST903135766.32
784SEMA4C levelsGCST904705726.32
785SPESP1 levelsGCST904707206.31
786LRRC37A2 levelsGCST904698026.31
787Biological Mother: Cancer, SkinGCST904754876.31
788ICAM5 levelsGCST904695026.31
789Atrophic disorders of skinFING000001296.31
790ENO2/PLXNA4 ratioGCST903146656.30
791ICD10 N84: Polyp of female genital tractGCST904542166.28
792Arachidoylcarnitine (C20) levelsGCST902001356.27
793Deep biteFING000003806.26
794Immature reticulocyte fraction (UKB data field 30280)GCST904680796.26
795Physical activity (Total log acceleration 12am-2am)GCST900614096.23
796SIRT1 levelsGCST904706416.23
797RNF43 levelsGCST904704866.23
798ICD10 O14: Pre-eclampsiaGCST904542336.22
799CRTAM/KLRD1 ratioGCST903142776.22
800COL1A1 levelsGCST902407446.19
801COPD-related respiratory insufficiencyFING000003526.19
802FCRL2/TNFRSF13B ratioGCST903148016.18
803CD27/TNFRSF13B ratioGCST903137776.17
804CASP8/DDX58 ratioGCST903136516.17
805aseg global volume SupraTentorialNotVentGCST900025966.17
806Nasal polyps | respiratoryUKBB000004946.16
807EBAG9/EDAR ratioGCST903145636.14
808Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T386ECGU0003866.13
809Left-hemisphere default mode network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027626.13
810Other noninfective gastroenteritis and colitisFING000010776.13
811Idiopathic pulmonary fibrosisFING000006596.13
812EDAR/YES1 ratioGCST903145946.12
813ICD10 C53: Malignant neoplasm of cervix uteriGCST904542026.11
814Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T387ECGU0003876.11
815N-acetyl-2-aminoadipate levelsGCST902002686.11
816Blood cell traits latent factor 17 (white cell)GCST905592596.10
817CWC15 levelsGCST904689206.09
818PALM2 levelsGCST904701526.09
819Benign leiomyoma with endometriosis (controls excluding all cancers)FING000001456.09
820QPCT/RNASET2 ratioGCST903157586.08
821Educational attainment (confirmatory factor analysis Factor 10)GCST903093446.08
822DSG2 levelsGCST904278256.06
8235alpha-pregnan-3beta,20alpha-diol disulfate levelsGCST901998386.05
824CD160/NCR1 ratioGCST903137326.03
825Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T383ECGU0003836.03
826LAYN/TNFRSF4 ratioGCST903152916.02
827Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary AdministrationUKBB000008376.01
828TNFRSF4 levelsGCST904709136.00
829Obesity related asthmaFING000008975.98
830FGFR4 levelsGCST904692345.98
831DTI TBSS MD Sagittal stratum RGCST903846025.96
832CALCOCO1/IRAG2 ratioGCST903136045.95
833Mucosal proctocolitisFING000008415.95
834PEAR1/PECAM1 ratioGCST903156415.94
835Disorders of sclera, cornea, iris and ciliary bodyFING000004585.94
836Tyrosine levelsGCST902434255.93
837TNFRSF19 levelsGCST900889475.92
838LPCAT2/SERPINB8 ratioGCST903153285.92
839GZMA/TNFRSF4 ratioGCST903150135.91
840ARG1 levelsGCST904683505.91
841FCRL6/KLRD1 ratioGCST903148075.91
842CEP43 levelsGCST904687155.90
843Telomere length (principal component 1)GCST904351445.89
844HypothyroidismGCST900186425.88
845Prescriptions - paracetamol | antipyreticUKBB000006965.88
846Prescriptions - antipyreticUKBB000006655.88
847Rheumatoid arthritis and other inflammatory polyarthropathies | musculoskeletalUKBB000007585.86
848Blood cell traits latent factor 12 (red cell)GCST905592545.86
849Time spend outdoors in summer | Sun exposureUKBB000008175.86
850Ulcerative rectosigmoiditisFING000013945.86
851CALCOCO1/IKBKG ratioGCST903136025.85
852Omega-3 fatty acids to total fatty acids percentageGCST905024485.84
853Principal component-derived dietary pattern 29GCST901330345.84
854Principal component-derived dietary pattern 9GCST901330145.83
855Plasma ascorbic acid 2-sulfate levels in chronic kidney diseaseGCST902648325.83
856Malignant neoplasm of breast, excluding all cancers (controls excluding all cancers)FING000007555.83
857PROK1 levelsGCST904703365.82
858Asthma-related pneumoniaFING000001195.81
859Operative procedures - No procedure performed | Summary OperationsUKBB000005845.81
860PBLD levelsGCST904701635.80
861Exposure to tobacco smoke outside home | SmokingUKBB000002295.79
862Number of days/week walked 10+ minutes | Physical activityUKBB000005355.78
863IDP dMRI ProbtrackX L3 ptr rGCST900043205.77
864TNF levelsGCST904709245.77
865EDAR/SERPINB1 ratioGCST903145865.77
866Left-hemisphere dorsal attention network to left-hemisphere default mode network white-matter structural connectivityGCST903026935.76
867XCL1 levelsGCST904710815.76
868Malignant neoplasm of oesophagus, excluding all cancers (controls excluding all cancers)FING000007665.75
869PAXX levelsGCST904701615.74
870Fasting blood insulinGCST0051855.74
871ConjunctivitisFING000003465.72
872X-21286 levelsGCST902005625.71
873HippSubfield lh volume Hippocampal-tailGCST900026685.70
874CASP1 levelsGCST904685435.69
875Cooked vegetable intake | DietUKBB000001475.69
876AHCY/HSPA1A ratioGCST903132115.66
877CDKN2D/ITGB1BP2 ratioGCST903139875.65
878DTI TBSS L3 Superior corona radiata RGCST903845485.65
879DTI autoptx L1 cst l tractGCST903851475.65
880Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T388ECGU0003885.64
881DNMBP/WWP2 ratioGCST903145225.63
882TNFSF13B levelsGCST904709205.63
883Later onset COPDFING000007145.62
884CXCL11/DKK1 ratioGCST903143345.61
885Malignant neoplasm of bladder (PheCode 189.21)GCST904755995.61
886MICB or MICA levelsGCST904699055.60
887SRC/TBL1X ratioGCST903158845.60
888Blood cell traits latent factor 3 (white cell)GCST905592455.59
889CLEC1B/HBEGF ratioGCST903140925.59
890IDP dMRI TBSS MO Posterior limb of internal capsule RGCST900039705.58
891Frontotemporal dementiaFING000005605.56
892GNLY/GZMA ratioGCST903149495.55
893IDP dMRI TBSS L1 Posterior limb of internal capsule LGCST900040945.54
894CirrhosisGCST900186065.53
895aparc-Desikan rh volume insulaGCST900028345.53
896Low hand grip strength (60 years and older) (EWGSOP)GCST900075265.51
897aparc-pial rh area postcentralGCST900031955.50
898Left-hemisphere dorsal attention network to right-hemisphere salience/ventral attention network white-matter structural connectivityGCST903026975.50
899Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T385ECGU0003855.49
900FAS levelsGCST904691925.48
901TNFRSF13B/TNFRSF9 ratioGCST903159325.47
902CHIT1 levelsGCST904687445.46
903SNRPB2 levelsGCST904706975.46
904Brainstem global volume MedullaGCST900027645.46
905Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T227ECGU0002275.46
906Allergic asthma (mode)FING000000665.46
907FCAMR levelsGCST904691965.44
908DTI autoptx MD fma tractGCST903852305.41
909Dihomo-linoleoylcarnitine (C20:2) levelsGCST902001445.40
910red cell diameter width (RDW, maximum, inv-norm transformed)GCST904763575.38
911CRACR2A/IRAG2 ratioGCST903142275.37
912FOXO1/USP8 ratioGCST903148795.37
913Cirrhosis, broad definition used in the article https://doi.org/10.1101/594523FING000003045.37
914Educational attainmentGCST0025985.36
915aparc-a2009s rh thickness G-temporal-middleGCST900037145.36
916GSTA1/PBLD ratioGCST903149945.36
917T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 127)GCST903206905.35
918Diseases of the digestive systemFING000004295.34
919NMNAT1 levelsGCST904700575.33
920GFRA2/IL12A_IL12B ratioGCST903149255.33
921mean platelet volume (MPV, maximum, inv-norm transformed)GCST904755175.33
922Ever had period extreme irritability | ManiaUKBB000002175.33
923Basophil countGCST900022935.33
924MICB_MICA/TEK ratioGCST903154465.31
925PSIP1 levelsGCST904703545.30
926aseg rh volume AmygdalaGCST900026425.30
927CSF2RB levelsGCST904688835.30
928MZB1/TNFRSF13B ratioGCST903155095.30
929ACVRL1/TNFRSF9 ratioGCST903131605.30
930DBNL/HSPA1A ratioGCST903144185.30
931aseg global volume CC-AnteriorGCST900026115.29
932OCLN levelsGCST904701145.29
933Principal component-derived dietary pattern 20GCST901330255.28
934FCRL5/TNFRSF13B ratioGCST903148055.28
935Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T496ECGA0004965.28
936EBAG9/TBCC ratioGCST903145685.27
937T1 FreeSurfer BA lh BA2 exvivo volumeGCST903855345.26
938Bipolar disorderGCST0037245.26
939JCHAIN levelsGCST904696615.25
940Oxalate (ethanedioate) levelsGCST901996725.24
941Juvenile rheumatoid arthirtisFING000007065.24
942aseg lh intensity Cerebellum-CortexGCST900037675.24
943Thyroid cancer (PheCode 193)GCST904756005.23
944DBI/EDAR ratioGCST903144085.23
945NMT1 levelsGCST904700595.21
946Colitis, primary sclerosing, strict definitionFING000003135.21
947PPM1B levelsGCST904702965.20
948IL19 levelsGCST904695685.19
949Acquired hypothyroidism (PheCode 244.2)GCST904756505.18
950Other retinal disordersFING000010945.18
951DTI TBSS L3 Anterior limb of internal capsule LGCST903845415.18
952PLXNB3/SNAP23 ratioGCST903156935.18
953BLVRB/CA3 ratioGCST903135235.17
954Sporadic miscarriageGCST0118885.17
955ITGB1BP2/MITD1 ratioGCST903152145.17
956Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers)FING000007725.16
957FOLH1 levelsGCST904271925.16
958Crohn's diseaseGCST904753185.15
959Cervical cancerGCST900185975.15
960PDLIM7/PLA2G4A ratioGCST903156375.15
961Urine glucosaminate levels in chronic kidney diseaseGCST902651795.14
962FLT3/FLT3LG ratioGCST903148595.13
963NOTCH1/SEMA7A ratioGCST903155455.12
964PolyarthrosisFING000011815.12
965Temporomandibular joint disordersFING000013545.12
966Principal component-derived dietary pattern 26GCST901330315.12
967Enthesopathies of lower limb, excluding footFING000005095.11
968Flat foot [pes planus] (acquired)FING000005455.10
969Principal component-derived dietary pattern 43GCST901330485.09
970T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60)GCST903208795.09
971CancerGCST900860525.08
972CNTNAP4 levelsGCST904688095.07
973APBB1IP/POLR2F ratioGCST903133005.06
974LTA/LTBR ratioGCST903153365.04
975ICAM3/LY9 ratioGCST903151215.03
976aparc-pial lh area lateralorbitofrontalGCST900031525.03
977Treatment/medication code - lansoprazole | MedicationsUKBB000008485.03
978neutrophil (fraction, mean, inv-norm transformed)GCST904755385.02
979CXCL11/ITGB1BP2 ratioGCST903143355.02
980DTI autoptx L1 slf r tractGCST903851615.02
981IDP T1 FIRST right caudate volumeGCST900024395.02
982Cereal consumption (bowls per week) (UKB data field 1458)GCST901329825.00
983Restless legs syndromeGCST904353874.99
984FUT3 or FUT5 levelsGCST904692804.97
985Other systemic involvement of connective tissue (FG)FING000011164.96
986EDAR/EGF ratioGCST903145734.96
987Dry age-related macular degeneration (includes geographic atrophy)FING000004804.95
988Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0) levelsGCST902000174.93
989Staphylococcus A fleurettii abundance in stoolGCST900325644.92
990Principal component-derived dietary pattern 21GCST901330264.92
991DAB2/ERBIN ratioGCST903143614.92
992AMOTL2 levelsGCST904682944.92
993GCHFR levelsGCST904693174.91
994Eicosenoylcarnitine (C20:1) levelsGCST902001484.91
995Allergic conjunctivitisFING000000674.91
996CDH17/SPINT1 ratioGCST903139444.90
997CD48 levelsGCST904686354.90
998Smoking status (weighted GWA)GCST902673034.90
999rfMRI connectivity (ICA100 edge 495)GCST900053484.88
1000Emphysema (PheCode 496.1)GCST904760284.87